by Boni E. Elewski, MD; Steven R. Feldman, MD, PhD; and Bruce E. Strober, MD, PhD
In the treatment of plaque psoriasis, small-molecule drugs such as apremilast are not as effective as the injectable therapies that target the inte......READ MORE
by Boni E. Elewski, MD; Steven R. Feldman, MD, PhD; and Bruce E. Strober, MD, PhD
Recent progress in targeted biologic therapies for plaque psoriasis reflects an understanding of the crucial role of the interleukin-23 (IL-23)/IL-......READ MORE
Patients with psoriasis can be screened for psoriatic arthritis relatively quickly, using a series of questions. Both the presence of joint involve......READ MORE
by Boni E. Elewski, MD; Steven R. Feldman, MD, PhD; and Bruce E. Strober, MD, PhD
Our featured experts discuss biologic treatment for plaque psoriasis in special populations with underlying conditions that might be exacerbated by......READ MORE
by Boni E. Elewski, MD; Steven R. Feldman, MD, PhD; and Bruce E. Strober, MD, PhD
There are multiple factors involved in the consideration of systemic treatments for plaque psoriasis. In addition to patient expectations and payor......READ MORE
Barriers that may undermine optimal care in psoriasis include patient-based, physician-based, and payor-based obstacles. Our featured expert explor......READ MORE
